Godavari Drugs Ltd

Godavari Drugs Annual General Meeting

Godavari Drugs held its 38th Annual General Meeting on September 25, 2026, via video conferencing. Shareholders approved financial statements, director re-appointment, and object clause alteration.

Godavari Drugs Annual General Meeting

Godavari Drugs Limited will close its register of members and share transfer books from September 19 to September 25, 2026, for its 38th Annual General Meeting.

Godavari Drugs Board Meeting Outcome

Godavari Drugs approved altering its Memorandum of Association to add a nutraceuticals business object. A revised notice for the 38th AGM was also approved.

Godavari Drugs Capital Structure Change

Godavari Drugs Limited allotted 7,86,690 equity shares to the promoter category following warrant conversion. The company received Rs. 5.25 Crore, representing the final 75% payment.

Value

₹5.25 Cr

Godavari Drugs Q1 FY27 Results: Net Profit ₹1.1 Cr, Up 10.0% YoY

Godavari Drugs Ltd reported revenue from operations of ₹28 Cr (+17.6% YoY) and net profit of ₹1.1 Cr (+10.0% YoY) for Q1 FY27.

Key figure

Net profit ₹1.1 Cr · +10.0% YoY

Godavari Drugs Board Meeting Date

Godavari Drugs Limited has scheduled a board meeting for August 24, 2026, to consider and approve the un-audited financial results for the quarter ended June 30, 2026.

Godavari Drugs Other Announcement

Godavari Drugs Ltd filed its quarterly shareholding pattern as of June 30, 2026. The document provides a detailed breakdown of promoter and public holdings.

Godavari Drugs Fund Raise of ₹44.12 Cr

Godavari Drugs Limited reported zero deviation in the utilization of ₹44.12 Crore raised through a preferential allotment. The funds are being deployed for capital expenditure.

Value

₹44.12 Cr

Godavari Drugs Q4 FY26 Results: Net Profit ₹1.3 Cr, Up 44.4% YoY

Godavari Drugs Ltd reported revenue from operations of ₹33.2 Cr (+30.2% YoY) and net profit of ₹1.3 Cr (+44.4% YoY) for Q4 FY26.

Key figure

Net profit ₹1.3 Cr · +44.4% YoY

Godavari Drugs Financial Results

Godavari Drugs Ltd reported annual revenue of ₹105.81 Crore for FY2026. The Board approved the audited results and appointed new internal and cost auditors.

Value

₹105.8 Cr

Godavari Drugs Board Meeting Date

Godavari Drugs scheduled a board meeting for May 27, 2026, to approve annual audited financial results. The trading window remains closed until May 29, 2026.

Godavari Drugs Other Announcement

Godavari Drugs Limited filed its Annual Secretarial Compliance Report for the financial year 2025-26. The report confirms overall regulatory adherence with minor observations on historical filing delays.

Godavari Drugs Price Movement Clarification

Godavari Drugs Limited clarified to BSE that recent share price movements are entirely market-driven. The company confirmed it has no undisclosed price-sensitive information and remains compliant with SEBI listing regulations regarding timely disclosures.